Jeffrey W. Scott

1.7k total citations
52 papers, 1.4k citations indexed

About

Jeffrey W. Scott is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Jeffrey W. Scott has authored 52 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 21 papers in Molecular Biology and 15 papers in Hematology. Recurrent topics in Jeffrey W. Scott's work include Histone Deacetylase Inhibitors Research (12 papers), Lung Cancer Treatments and Mutations (10 papers) and Acute Myeloid Leukemia Research (9 papers). Jeffrey W. Scott is often cited by papers focused on Histone Deacetylase Inhibitors Research (12 papers), Lung Cancer Treatments and Mutations (10 papers) and Acute Myeloid Leukemia Research (9 papers). Jeffrey W. Scott collaborates with scholars based in United States, Germany and Switzerland. Jeffrey W. Scott's co-authors include James H. Finke, Andrew Spencer, D. R. Crapper, Oliver G. Ottmann, Umberto De Boni, Kapil N. Bhalla, Daniel J. DeAngelo, Yvonne Lau, H. Miles Prince and Peter Atadja and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Jeffrey W. Scott

51 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey W. Scott United States 19 569 444 253 217 201 52 1.4k
Stefan Vasile United States 19 779 1.4× 230 0.5× 124 0.5× 61 0.3× 71 0.4× 54 1.5k
Hongfeng Yuan China 23 1.1k 1.9× 472 1.1× 159 0.6× 102 0.5× 72 0.4× 41 1.9k
Stefano Caramuta Sweden 16 833 1.5× 211 0.5× 145 0.6× 15 0.1× 63 0.3× 25 1.4k
Ute Schellenberger United States 18 558 1.0× 297 0.7× 95 0.4× 51 0.2× 86 0.4× 44 1.3k
Corbin E. Meacham United States 8 1.3k 2.3× 900 2.0× 209 0.8× 204 0.9× 22 0.1× 10 2.5k
Trudi Harris Australia 24 574 1.0× 175 0.4× 386 1.5× 62 0.3× 15 0.1× 41 1.5k
Alexander Starodub United States 17 498 0.9× 1.1k 2.5× 371 1.5× 47 0.2× 19 0.1× 109 1.6k
Zhong Guan China 14 300 0.5× 219 0.5× 63 0.2× 16 0.1× 68 0.3× 57 786
Conchita Vens Netherlands 22 1.1k 1.9× 760 1.7× 463 1.8× 15 0.1× 27 0.1× 61 2.1k
Ashish Juvekar United States 11 804 1.4× 468 1.1× 131 0.5× 55 0.3× 33 0.2× 22 1.3k

Countries citing papers authored by Jeffrey W. Scott

Since Specialization
Citations

This map shows the geographic impact of Jeffrey W. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey W. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey W. Scott more than expected).

Fields of papers citing papers by Jeffrey W. Scott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey W. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey W. Scott. The network helps show where Jeffrey W. Scott may publish in the future.

Co-authorship network of co-authors of Jeffrey W. Scott

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey W. Scott. A scholar is included among the top collaborators of Jeffrey W. Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey W. Scott. Jeffrey W. Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hurtado, Felipe K., Filippo de Braud, Javier de Castro, et al.. (2021). Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors. Cancer Chemotherapy and Pharmacology. 87(4). 475–486. 9 indexed citations
2.
Weger, Vincent A. de, Sanjay Goel, Roger von Moos, et al.. (2017). A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 81(1). 73–80. 4 indexed citations
3.
Lau, Yvonne, Wen Gu, Tiffany Lin, et al.. (2017). Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 79(6). 1119–1128. 15 indexed citations
4.
Infante, Jeffrey R., Ramesh K. Ramanathan, Daniel J. George, et al.. (2015). A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258). Cancer Chemotherapy and Pharmacology. 75(4). 729–737. 4 indexed citations
5.
Scheid, Christof, Donna Reece, Meral Beksaç, et al.. (2014). Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. European Journal Of Haematology. 95(4). 316–324. 31 indexed citations
6.
Sharma, Sunil, Carolyn D. Britten, Joanne Mortimer, et al.. (2014). The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 74(4). 867–874. 5 indexed citations
7.
Sharma, Sunil, Elisabeth G.E. de Vries, Jeffrey R. Infante, et al.. (2013). Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Investigational New Drugs. 32(1). 135–144. 39 indexed citations
8.
Sharma, Sunil, Ramesh K. Ramanathan, Daniel J. George, et al.. (2013). A randomized, crossover phase I study to assess the effects of formulation and meal consumption on the bioavailability of dovitinib (TKI258).. Journal of Clinical Oncology. 31(15_suppl). 2593–2593. 2 indexed citations
9.
DeAngelo, Daniel J., Andrew Spencer, Thomas Fischer, et al.. (2009). Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.. Blood. 114(22). 2898–2898. 10 indexed citations
10.
Ottmann, Oliver G., Andrew Spencer, H. Miles Prince, et al.. (2008). Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.. Blood. 112(11). 958–958. 46 indexed citations
11.
Sharma, Shringi, Elisabeth G.E. de Vries, J. R. Infante, et al.. (2008). Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3538–3538. 19 indexed citations
12.
Scott, Jeffrey W., et al.. (2004). Vaccines and hurricanes don't mix. Paediatrics & Child Health. 9(7). 453–456. 2 indexed citations
13.
Kristeleit, Rebecca, Peter Atadja, Amita Patnaik, et al.. (2004). Effects of the histone deacetylase inhibitor (HDACI) LAQ824 on histone acetylation, Hsp70 and c-Raf in peripheral blood lymphocytes from patients with advanced solid tumours enrolled in a phase I clinical trial. Journal of Clinical Oncology. 22(14_suppl). 3023–3023. 9 indexed citations
14.
Wooten, Marc D., Jeffrey W. Scott, Ashley M. Miller, & Erin Boh. (1998). Chronic Myelogenous Leukemia and Porphyria Cutanea Tarda in a Patient With Limited Systemic Sclerosis. Southern Medical Journal. 91(5). 493–495. 11 indexed citations
15.
Scott, Jeffrey W.. (1992). Multiplier-Free Interpolation for Oversampled Digital-to-Analog Conversion. Journal of the Audio Engineering Society. 2 indexed citations
16.
Scott, Jeffrey W., et al.. (1991). 18-Bit Stereo D/A Converter with Integrated Digital and Analog Filters. Journal of the Audio Engineering Society. 17 indexed citations
17.
Scott, Jeffrey W., et al.. (1983). ‘Ohio CR-6’ Tomato1. HortScience. 18(1). 114–115. 8 indexed citations
18.
Scott, Jeffrey W., et al.. (1982). Genetic Restriction of Interferon Production in Immune Response to Listeria Monocytogenes. Journal of Interferon Research. 2(1). 111–116. 1 indexed citations
19.
Finke, James H., et al.. (1981). CTL Helper Factor(s) Produced by Peritoneal Cells of Mice Immunized to Listeria monocytogenes : Relationship to Interferon*. Journal of Interferon Research. 1(2). 271–285. 9 indexed citations
20.
Boni, Umberto De, et al.. (1976). Neurofibrillary degeneration induced by systemic aluminum.. PubMed. 35(4). 285–94. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefan Vasile Breakdown of academic impact, for papers by Hongfeng Yuan Breakdown of academic impact, for papers by Stefano Caramuta Breakdown of academic impact, for papers by Ute Schellenberger Breakdown of academic impact, for papers by Corbin E. Meacham Breakdown of academic impact, for papers by Trudi Harris Breakdown of academic impact, for papers by Alexander Starodub Breakdown of academic impact, for papers by Zhong Guan Breakdown of academic impact, for papers by Conchita Vens Breakdown of academic impact, for papers by Ashish Juvekar
Rankless by CCL
2026